文献速递心律失常血脂与心血管预防

2000至2016年英国全科医疗中心房颤患病率与治疗趋势

Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016.
PubMed 文献 · Heart · 2018-07-10

该研究基于英国全科电子病历数据库,于2000至2016年开展17次序贯横断面分析,评估房颤患病率、卒中风险及抗凝治疗比例。结果显示,年龄-性别标准化房颤患病率从2.14%升至3.29%,高危患者抗凝治疗比例从35.4%增至75.5%,中危患者从32.8%升至47.1%,低危患者从19.9%降至9.7%。

要点

  • 2000至2016年英国房颤患病率从2.14%增至3.29%。
  • 高危卒中风险房颤患者抗凝治疗比例从35.4%升至75.5%。
  • 低危患者抗凝比例从19.9%降至9.7%。

核心结论

  • 2000至2016年,英国记录房颤患病率在所有年龄组和性别中均增加。
  • 符合条件房颤患者的抗凝治疗比例增加逾一倍,2011年后改善显著。
  • 不符合条件患者的抗凝使用减少。

研究设计与样本

  • 研究基于英国全科医生电子初级保健记录大型数据库,于2000至2016年开展17次序贯横断面分析。
  • 分析确定房颤诊断患病率、房颤患者卒中风险及当前接受抗凝治疗比例。
  • 卒中风险采用CHA2DS2-VASc评分评估。

主要发现

  • 年龄-性别标准化房颤患病率从2000年2.14%(95%CI 2.11%至2.17%)增至2016年3.29%(95%CI 3.27%至3.32%)。
  • 高卒中风险患者抗凝治疗比例从2000年35.4%(95%CI 34.7%至36.1%)增至2016年75.5%(95%CI 75.1%至75.8%),随时间变化p<0.001。
  • 中等卒中风险患者抗凝治疗比例从32.8%(95%CI 30.5%至35.2%)增至47.1%(95%CI 45.4%至48.7%),p<0.001。
  • 低卒中风险患者抗凝治疗比例从19.9%(95%CI 17.8%至22.2%)降至9.7%(95%CI 8.4%至11.1%),p<0.001。
  • 2016年,最高和最低绩效五分位诊所的符合条件患者治疗比例分别为82.9%(95%CI 82.2%至83.7%)和62.0%(95%CI 61.0%至63.0%);2006至2016年个体诊所绩效线性加权κ=0.10(95%CI 0.02至0.19)。

关键数值与推荐

  • 卒中风险使用CHA2DS2-VASc评分评估。
  • 高卒中风险患者抗凝治疗比例从35.4%增至75.5%(p<0.001)。
  • 中等卒中风险患者抗凝治疗比例从32.8%增至47.1%(p<0.001)。
  • 低卒中风险患者抗凝治疗比例从19.9%降至9.7%(p<0.001)。

临床怎么用

  • 研究提示应持续提高符合抗凝条件房颤患者的治疗率。
  • 需关注并减少不符合条件患者的抗凝使用。
  • 诊所间抗凝处方绩效差异显著,需针对性改进。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Atrial fibrillation (AF) is the most common cardiac arrhythmia and an important risk factor for stroke. Treatment with anticoagulants substantially reduces risk of stroke. Current prevalence and treatment rates of AF in the UK as well as changes in recent years are not known. The aim of this analysis was to determine trends in age-sex specific prevalence and treatment of AF in the UK from 2000 to 2016. METHODS: 17 sequential cross-sectional analyses were carried out between 2000 and 2016 using a large database of electronic primary care records of patients registered with UK general practitioners. These determined the prevalence of patients diagnosed with AF, the stroke risk of those with AF and the proportion of AF patients currently receiving anticoagulants. Stroke risk was assessed using CHA2DS2-VASc score. RESULTS: Age-sex standardised AF prevalence increased from 2.14% (95% CI 2.11% to 2.17%) in 2000 to 3.29% (95% CI 3.27% to 3.32%) in 2016. Between 2000 and 2016, the proportion of patients with AF prescribed anticoagulants increased from 35.4% (95% CI 34.7% to 36.1%) to 75.5% (95% CI 75.1% to 75.8%) in those with high stroke risk (p for change over time <0.001) and from 32.8% (95% CI 30.5% to 35.2%) to 47.1% (95% CI 45.4% to 48.7%) in those with moderate stroke risk (p<0.001). In patients with low risk of stroke, the proportion decreased from 19.9% (95% CI 17.8% to 22.2%) to 9.7% (95% CI 8.4% to 11.1%) (p<0.001). Anticoagulant prescribing performance varied between practices; in 2016, the proportion of eligible patients treated was 82.9% (95% CI 82.2% to 83.7%) and 62.0% (95% CI 61.0% to 63.0%) in the highest-performing and lowest-performing practice quintiles, respectively. There was poor agreement in individual practice performance over time from 2006 to 2016: linear-weighted κ=0.10 (95% CI 0.02 to 0.19). CONCLUSIONS: From 2000 to 2016, the prevalence of recorded AF has increased in all age groups and both sexes. Anticoagulant treatment of eligible patients with AF has more than doubled, with marked improvements since 2011, alongside a reduction in the use of anticoagulants in ineligible patients with AF.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Adderley NJ, Ryan R, Nirantharakumar K, et al. Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016. Heart. 2018. PMID: 29991504. doi:10.1136/heartjnl-2018-312977

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。